Is Edwards Lifesciences Stock Underperforming the Dow?
/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
With a market cap of $45.6 billion, Edwards Lifesciences Corporation (EW) offers products and technologies for treating advanced cardiovascular diseases internationally. The company’s product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart.
Companies valued at $10 billion or more are generally described as “large-cap stocks”, and Edwards Lifesciences fits this description perfectly. The company specializes in less invasive treatments for patients with heart valve disorders and continues to pioneer technologies that improve patient outcomes and advance cardiovascular care.
Edwards Lifesciences’ stock dropped 18.4% from its 52-week high of $95.25. Shares of EW have gained 6.8% over the past three months, outperforming the broader Dow Jones Industrials Average's ($DOWI) 1.6% decline.
In the long term, EW stock has soared 5.1% on a YTD basis, whereas DOWI has decreased marginally. However, shares of Edwards Lifesciences have collapsed 10.7% over the past 52 weeks, significantly underperforming the Dow Jones’ 9.1% rise over the same time frame.
Since late April, EW stock has climbed above its 50-day and 200-day moving averages.
Shares of Edward Lifesciences rose 6.6% following the release of its solid Q1 2025 results on Apr. 23. The company reported sales of $1.4 billion, reflecting a 6.2% year-over-year increase, and surpassing the Wall Street expectations. Adjusted sales from the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment surged 61.5% to $114.8 million. Its adjusted EPS came in at $0.64, up 16.4% from the same quarter last year and surpassed the consensus estimate by 6.7%.
Looking ahead, EW expects total sales for fiscal 2025 to range between $5.7 billion and $6.1 billion, with EPS guidance between $2.40 and $2.50.
However, rival Abbott Laboratories (ABT) has outperformed EW stock. ABT stock has climbed 18.4% on a YTD basis and has surged 29.8% over the past 52 weeks.
Despite Edwards Lifesciences' underperformance over the past year, analysts have a moderately optimistic outlook. With 29 analysts covering the stock, the consensus rating is “Moderate Buy,” and it is currently trading below the mean price target of $80.67.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.